ClinicalTrials.gg
Status unknownNCT05861154Updated May 16, 2023

Effectiveness of Laser Photobiomodulation Therapy in Reducing Child Pain During Local Anesthesia Injection

An interventional study of Photobiomodulation and Benzocaine Gel in Local Anesthesia Injection Pain, sponsored by Aliaa Hamouda. Status unknown at 1 site in Egypt. Open to participants aged 5 Years to 7 Years. Per ClinicalTrials.gov, last updated 2023-05-16.

Sponsored by Aliaa Hamouda · Not applicable, Interventional, and Supportive care

The sponsor has not verified this record recently (last verified May 2023), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Dec 2022, registered Apr 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
5 Years to 7 Years
Sex
All
01

Study summary

This study aimed to evaluate the impact of laser photobiomodulation therapy used as pre-anesthetic technique to reduce child pain during local anesthesia administration

02

Conditions studied

  • Local Anesthesia Injection Pain
03

In context

Lead sponsor

Aliaa Hamouda is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 7 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completion of the written informed consent form by parents/guardian.
  • Children with dental behavior score of 3 or 4 according to the Frankel behavior rating scale.
  • Patients whom their maxillary primary molars are indicated for pulpotomy and SSC restoration.
  • Lack of history of allergy to the materials used for anesthesia and sulfite
  • Children free of any systemic disease or special health care needs (ASA 1)

Exclusion criteria

Exclusion Criteria:

  • Children who receive any analgesic drugs at least 24 hours before treatment.
  • Any inflammation or lesion in the injection site
  • Patients who have previous bad experience of dentistry were excluded to eliminate the possible impact of the child's previous painful or stressful experiences
  • Child coming for emergency treatment of pain
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Photobiomodulation

    Device: Photobiomodulation

  • Active comparator
    Topical anesthesia

    Drug: Benzocaine Gel

Interventions

  • DevicePhotobiomodulation

    A diode laser (Sirolaser blue laser system, Sirona Dental Systems GmbH, Fabrikstraße 31, 64625 Bensheim, Germany) of Wavelength 660 nm will be used and the laser parameters will be set as follows: Power 0.1 W, energy 6 J, Continuous wave, Irradiation time 60 Seconds; energy Tip area 0.5 cm2, fluence 12 J/cm2 will be applied at the site of needle penetration. It should be noted that before each application, the output of the laser device will be checked using the aiming beam on flat surface; both the patient and the operator will wear safety goggles during the irradiation.

  • a 20% Benzocaine topical anaesthetic gel will be applied. To increase the absorption of the topical anaesthetic gel, soft tissues will be dried with (2 x 2 cm) gauze. Topical anaesthetic gel will be applied at the site of needle penetration and left in contact with the soft tissues for one minute in order to to maximize its effect.

06

What researchers measure

Primary outcomes

  1. Heart Rate

    A brief demonstration of the pulse oximeter will be performed, and the patient will be instructed to remain still and avoid hand movement in order to obtain accurate readings. The pulse oximeter will be placed on the patient's index finger to measure the baseline heart rate (prior to administering the LA), and another measurement will be taken during the LA administration. Heart rate will be recorded at 2-minute intervals and the mean heart rate measurement will be calculated.

    Time frame: during local anesthesia administration

  2. Pain Reaction

    The Sound, Eye, Motor (SEM) Scale will be used to assess pain. It encompasses the following parameters: (1) Sound, (2) Eye and (3) Motor. The sounds, eye symptoms and body movements of each child will be independently evaluated by a blind impartial observer using the recorded video tapes. The slightest manifestation of the patient's sound, eyes, or motion is graded in four levels: comfort, mild, moderate, and severe discomfort, and subsequently given grades 1, 2, 3, 4, respectively. The SEM score will be calculated by adding the three parameter grades.

    Time frame: during local anesthesia administration

  3. Perceived Pain

    To subjectively record pain during LA injection, a modified face scale will be used. It comprises three schematic faces with different facial expressions for happy and sad faces representing: (A) satisfaction; (B) indifference; and (C) dissatisfaction, respectively. Each child will be taught before injection how to use the scale by modelling and then asking each participant to recall the last time she or he felt something painful and select the facial expression that best represented his or her experience of discomfort.

    Time frame: immediately after local anesthesia administration

07

Study locations

1 of 1 sites recruiting
  • Faculty of Dentistry, Alexandria University
    Alexandria, 21527, Egypt
    Recruiting
08

References and documents

Publications

  • Hamouda AA, El-Habashy LM, Khalil A. The use of laser photobiomodulation as pre-anesthetic tissue management technique in reducing injection pain in children. BMC Oral Health. 2024 Jun 22;24(1):717. doi: 10.1186/s12903-024-04430-3. PubMed 38909229 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2022 (actual). Primary completion is estimated for Jul 2023, 7 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2023
First posted
May 16, 2023
StartActual
Dec 1, 2022
Primary completionEst.
Jul 2023
CompletionEst.
Jul 2023
Last update
May 16, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05861154
Lead sponsor
Aliaa Hamouda
Responsible party
Aliaa Hamouda (Assistant Lecturer of Pediatric Dentistry, Alexandria University) — Sponsor-investigator
First posted
May 16, 2023
Start date
Dec 1, 2022
Primary completion
Jul 2023 (estimated)
Completion
Jul 2023 (estimated)
Last update
May 16, 2023

Study contacts

Aliaa Hamouda, MSc
Contact
aliaa.hamouda@alexu.edu.eg
010062680616 ext. +2
Aliaa Hamouda, MSc
principal investigator · Alexandria University
Amani Khalil, PhD
study chair · Alexandria University
Laila El-Habashy, PhD
study director · Alexandria University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion